Clinical Trial

Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study intends to explore the role of PD1/PDL1 antibody with selective combination of Sintilimab, IBI310 and Lenvatinib in organ preservation in non-metastatic dMMR/MSI-H gastric or colon cancers with mismatch repair deficiency or high microsatellite instability
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-08-29.
Trial Details
NCT Number NCT06580574
Lead Sponsor Peking University
Conditions Gastric Cancer, Colon Cancer, MSI-H, DMMR Cancer
Enrollment 34 participants
Start Date 2024-09-13
Primary Completion 2029-06-01 (estimated)
Study Completion 2029-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-15